Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908445 | 0.86 | KMT2A (0.41) | KMT2ATDP1MAPTLMNASMN1; SMN2 | |
| SCHEMBL27482029 | 0.83 | KMT2A (0.49) | KMT2ATDP1GAAATAD2 | |
| SCHEMBL27677766 | 0.83 | PDE3B (0.48) | TDP1MAPTLMNASMN1; SMN2 | |
| SCHEMBL153162 | 0.83 | KMT2A (0.73) | KMT2ATDP1MAPTGAASMN1; SMN2 | |
| SCHEMBL1525934 | 0.83 | KMT2A (0.73) | KMT2ATDP1MAPTLMNAATAD2 | |
| SCHEMBL28628364 | 0.82 | LMNA (0.39) | KMT2ATDP1LMNAGAAATAD2 | |
| SCHEMBL29466673 | 0.82 | KMT2A (0.48) | KMT2ATDP1GAAATAD2 | |
| SCHEMBL15090423 | 0.80 | GAA (0.45) | KMT2ATDP1LMNAGAAATAD2 | |
| SCHEMBL27663548 | 0.80 | LMNA (0.37) | KMT2ATDP1LMNA | |
| SCHEMBL1227718 | 0.78 | GAA (0.47) | MAPTLMNAGAAATAD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6125 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-12552858-B2 | Methods and compositions for delivering mRNA coded antibodies | TRANSLATE BIO, INC. (US) | 2026-02-17 | — | — | US | claimed |
| WO-2025137576-A1 | MULTIPLE SPECIFIC ANTIBODIES TARGETING CD19, CD20, AND/OR CD47 | NUTCRACKER THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| CN-115666638-A | Treatment involving non-immunogenic RNA for antigen vaccination | 生物技术欧洲股份公司 | 2023-01-31 | — | — | CN | claimed |
| US-11421038-B2 | RNA-coded antibody | CUREVAC AG (DE) | 2022-08-23 | — | — | US | claimed |
| EP-3115064-B1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2021-11-24 | — | — | EP | claimed |
| EP-2970456-B1 | METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES | TRANSLATE BIO INC (US) | 2021-05-19 | — | — | EP | claimed |
| EP-3636669-A1 | RNA-CODED ANTIBODY | CureVac AG (DE) | 2020-04-15 | — | — | EP | claimed |
| US-20190284260-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2019-09-19 | — | — | US | claimed |
| EP-2838541-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | Agency For Science, Technology And Research (SG) | 2015-02-25 | — | — | EP | claimed |
| WO-2014152909-A1 | ALTERATION OF GENE EXPRESSION BY SYNTHETIC piRNAs AND BY ALTERATION OF piRNA FUNCTION | IBIS BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| US-20130195867-A1 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| US-20100189729-A1 | RNA-CODED ANTIBODY | CURVAC GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| EP-2101823-A2 | RNA-CODED ANTIBODY | Curevac GmbH (DE) | 2009-09-23 | — | — | EP | claimed |
| WO-2008083949-A2 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2008-07-17 | — | — | WO | claimed |
| US-5998596-A | Inhibition of protein kinase activity by aptameric action of oligonucleotides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-07 | — | — | US | claimed |